If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
6.15    0.10 (1.65%)
Bid:
6.10
Ask:
6.20
Spread: 0.10 (1.639%)
Market Cap: £65.78m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Form 8.3 - Shield Therapeutics plc

9 May 2023 11:04

Form 8.3 - Shield Therapeutics plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Jupiter Fund Management Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeShield Therapeutics plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held: For an opening position disclosure, state the latest practicable date prior to the disclosure5th May 2023
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1.5p Ordinary
 InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:37,146,9926.34  
(2) Cash-settled derivatives:    
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:37,146,9926.34  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:None
Details, including nature of the rights concerned and relevant percentages:None

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
None   

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
NONE    
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
NONE       

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
NONE    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
None   

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:9th May 2023
Contact name:Jon Watson
Telephone number:0203 817 1672

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
21st May 20217:00 amRNSUS update
18th May 20217:00 amRNSAEGIS-H2H study results published in IBD
17th May 20217:00 amRNSCommencement of trading on the OTCQX Best Market
13th May 20213:00 pmRNS2020 Annual Report and 2021 AGM Notice
10th May 20217:00 amRNSAppointment of Two Non-Executive Directors
6th May 20211:44 pmRNSTotal Voting Rights Update
29th Apr 20217:00 amRNSPreliminary Results
22nd Apr 20217:00 amRNSNotice of Results
7th Apr 20219:33 amRNSHolding(s) in Company
7th Apr 20219:31 amRNSHolding(s) in Company
6th Apr 202111:05 amRNSSecond Price Monitoring Extn
6th Apr 202111:00 amRNSPrice Monitoring Extension
6th Apr 20217:00 amRNSHolding(s) in Company
31st Mar 20213:01 pmRNSTotal Voting Rights Update
31st Mar 20213:00 pmRNSBlock Listing 6 Monthly Return
30th Mar 20217:00 amRNSInvestor presentation
26th Mar 20217:00 amRNSStudy demonstrates effectiveness of ferric maltol
24th Mar 20215:40 pmRNSBlock Listing Application
23rd Mar 20215:53 pmRNSHolding(s) in Company
23rd Mar 202112:23 pmRNSHolding(s) in Company
22nd Mar 20217:00 amRNSShield appoints new Chief Financial Officer
18th Mar 20212:02 pmRNSResult of General Meeting & Open Offer
15th Mar 20215:21 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSAustralia's TGA approves Feraccru
5th Mar 20214:54 pmRNSPDMR Transaction Notification
4th Mar 20216:17 pmRNSPDMR/PCA Transaction Notification
3rd Mar 20211:40 pmRNSInvestor Presentation
1st Mar 20217:00 amRNSPublication of Circular and Notice of GM
26th Feb 20214:09 pmRNSSuccessful completion of £25 million Fundraise
26th Feb 202112:30 pmRNSTotal Voting Rights Update
26th Feb 202111:05 amRNSSecond Price Monitoring Extn
26th Feb 202111:00 amRNSPrice Monitoring Extension
26th Feb 20219:30 amRNSPlacing and Subscription to raise up to £25m
19th Feb 202111:05 amRNSSecond Price Monitoring Extn
19th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20218:00 amEQSEdison Investment Research Limited: Shield Therapeutics (STX): Beefing up for the US opportunity
29th Jan 20212:38 pmRNSShareholder loan facilities
29th Jan 20217:00 amRNSTotal Voting Rights Update
21st Jan 20215:41 pmRNSDirector/PDMR Shareholding
19th Jan 20212:20 pmRNSDirector/PDMR Shareholding
15th Jan 202110:00 amRNSInvestor presentation
15th Jan 20217:00 amRNSBusiness and trading update
14th Jan 202111:05 amRNSSecond Price Monitoring Extn
14th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity
31st Dec 20207:00 amRNSTotal Voting Rights Update
22nd Dec 202010:06 amRNSHolding(s) in Company
21st Dec 20207:00 amRNSInvestor Presentation
18th Dec 20205:21 pmRNSGrant of share options to the CEO
18th Dec 20205:15 pmRNSPDMR Exercise of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.